Literature DB >> 17554558

Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-gamma receptor 2 deficiency.

Amy V Rapkiewicz1, Smita Y Patel, Steven M Holland, David E Kleiner.   

Abstract

The control of intracellular microorganisms such as mycobacteria is largely dependent on the adaptive immune response, specifically the interaction of T helper cells and antigen presenting cells such as macrophages. The interferon gamma (IFN-gamma) pathway activation is crucial for containment and killing of mycobacteria, as evidenced by the fact that defects in this pathway often result in profound infections with both tuberculous and non-tuberculous mycobacteria. We herein report a case of a child with autosomal recessive IFN-gamma receptor 2 (IFN-gammaR2) deficiency who developed hepatic venopathy secondary to disseminated Mycobacterium avium complex (MAC) infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554558     DOI: 10.1007/s00428-007-0427-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

Review 1.  Cytokine therapy of mycobacterial infections.

Authors:  S M Holland
Journal:  Adv Intern Med       Date:  2000

Review 2.  Noncirrhotic portal hypertension.

Authors:  S Hillaire; D Valla; D Lebrec
Journal:  Clin Liver Dis       Date:  1997-05       Impact factor: 6.126

Review 3.  Sarcoidosis of the liver and bile ducts.

Authors:  K G Ishak
Journal:  Mayo Clin Proc       Date:  1998-05       Impact factor: 7.616

Review 4.  Immunotherapy of mycobacterial infections.

Authors:  S M Holland
Journal:  Semin Respir Infect       Date:  2001-03

5.  A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent.

Authors:  H S Fonga-Djimi; F Gottrand; M Bonnevalle; J P Farriaux
Journal:  Eur J Pediatr       Date:  1995-10       Impact factor: 3.183

6.  Mycobacterium avium complex peritonitis in an AIDS patient.

Authors:  J J Huh; L A Panther
Journal:  Scand J Infect Dis       Date:  2001

7.  Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency.

Authors:  Carla M Ward; Harumi Jyonouchi; Sergei V Kotenko; Sergey V Smirnov; Rakesh Patel; Helen Aguila; George McSherry; Barry Dashefsky; Steven M Holland
Journal:  Eur J Pediatr       Date:  2006-11-21       Impact factor: 3.183

8.  A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states.

Authors:  Sergio D Rosenzweig; Susan E Dorman; Gulbu Uzel; Stephen Shaw; Amy Scurlock; Margaret R Brown; Rebecca H Buckley; Steven M Holland
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

9.  Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection.

Authors:  S E Dorman; S M Holland
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

Review 10.  Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling.

Authors:  M H Haverkamp; J T van Dissel; S M Holland
Journal:  Microbes Infect       Date:  2006-01-19       Impact factor: 2.700

View more
  2 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Interferon alpha treatment of patients with impaired interferon gamma signaling.

Authors:  H I Bax; A F Freeman; L Ding; A P Hsu; B Marciano; E Kristosturyan; T Jancel; C Spalding; J Pechacek; K N Olivier; L A Barnhart; L Boris; C Frein; R J Claypool; V Anderson; C S Zerbe; S M Holland; E P Sampaio
Journal:  J Clin Immunol       Date:  2013-03-20       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.